A comprehensive view of Shionogi & Co. Ltd.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva cabotegravir, rilpivirine is as effective as daily oral Biktarvy BIC/FTC/TAF for the treatment of HIV-1

Japan orders 1 million courses of Japanese drugmaker Shionogi’s oral COVID-19 antiviral Xocova after granting the drug emergency approval; Merck’s Lagevrio, Pfizer’s Paxlovid COVID-19 antivirals previously received approval in the country

Japan approves domestically developed COVID-19 oral antiviral Xocova developed by Shionogi; company to seek US approval for the drug

ViiV Healthcare announces recipients of largest philanthropic fund in the US dedicated to HIV prevention for Black women; 17 groups awarded grants to raise awareness, connect women to HIV care, drive narrative change among providers

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count